Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Jan 6;25(6):1142–1151. doi: 10.1016/j.bbmt.2019.01.002

Table 1:

Disease and transplant characteristics of evaluated patients

(N=101)
Age at transplant
 Median, Range 59 (30.0–73.4)
 < 50 13 (12.9%)
 50 – 65 75 (74.3%)
 > 65 13 (12.9%)
Gender: Male 60 (59.4%)
Diagnosis
 PMF 62 (61.4%)
 Post ET MF 20 (19.8%)
 Post PV MF 18 (17.8%)
 MPN-U 1 (1.0%)
DIPSS
 Low Risk 9 (8.9%)
 Int-1 36 (35.6%)
 Int-2 41 (40.6%)
 High Risk 15 (14.9%)
MIPSS-70
 Missing 21
 High Risk 48 (60.0%)
 Intermediate Risk 29 (36.3%)
 Low Risk 3 (3.8%)
Cytogenetics
 Missing 15
 Favorable 61 (70.9%)
 Unfavorable 25 (29.1%)
3 or more somatic mutations
 Yes 30 (29.7%)
HMR: Presence of one of the mutations ASXL1/SRSF2/IDH1/2/EZH2/T
P53
 Yes 37 (36.6%)
MPN Triple Negative (no for JAK2,MPL and CALR)
 Yes 22 (21.8%)
Spleen status
 Splenectomy 11 (10.9%)
 Splenomegaly 69 (68.3%)
 No splenomegaly 21 (20.8%)
Time from Diagnosis to Transplant (years)
 Median, range 1.9 (0.1–28.4)
Donor
 MRD 46 (45.5%)
 MUD 52 (51.5%)
Mismatch 3 (3.0%)
Donor age
 Missing 17
Median, Range 45.5 (18.0–73.0)
Conditioning Regimen
 MAC 18 (17.8%)
 RIC 83 (82.2%)